Savicell Diagnostics Overview
Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer. The company aspires to improve adherence to routine medical screenings through the use of patient-friendly blood tests. Savicell Diagnostics is a majority-owned subsidiary of Savicell Corporation, a Nevada-based corporation.
Latest News
Not applicable
"הצלחנו להציל חיים": כך פועלת הבדיקה שמזהה סרטן בתוך 5 שעות | חדשות 13
A new, simple, and affordable blood test developed in Israel can detect lung cancer within a few hours, potentially saving lives. This test, which has not yet been officially approved, successfully identified the disease in one of the trial participants, saving their life. The test works by asking white blood cells if they have encountered cancer. This breakthrough represents a significant advancement in medical technology and cancer detection, particularly for lung cancer, which is notoriously difficult to diagnose early.
growth-positive
Savicell touts high accuracy results for its liquid biopsy platform
Savicell Diagnostics Ltd. has reported high accuracy results for its liquid biopsy platform Immunobiopsy in identifying lung cancer. The platform achieved 97% sensitivity and 97% specificity in a study with 245 participants. This news is growth-positive for the company.
Customers
growth-positive
Orgenesis to collaborate with Savicell on ImmunoBiopsy platform
Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to develop and validate diagnostic kits for quality control and monitoring purposes in the manufacturing and processing of its cell and gene therapies. Orgenesis will have exclusive rights to use and sell the kits, which will be used within its point-of-care platform. The collaboration aims to enhance the potency of therapies and develop companion diagnostics for targeted patient treatment. The initial focus will be on lung cancer treatments, with plans to expand to other cancer types and diseases. The collaboration will leverage Savicells ImmunoBiopsy platform. The CEO of Orgenesis sees promise in early cancer detection using the technology.
Partners
growth-positive
Startup says its blood test can detect early-stage lung cancer
Israeli startup Savicell Diagnostics has developed a blood test for the early detection of lung cancer. The companys ImmunoBiopsy test analyzes the metabolic profile of the immune system to identify signs of the disease. The test has shown promising results in distinguishing between various ailments, including cancers, autoimmune diseases, and infectious diseases. Savicell has already conducted testing at leading Israeli hospitals and has a more advanced product for lung cancer detection. While the technology is promising, there are still limitations in terms of sensitivity and accuracy. Other companies in the field of liquid biopsy and early detection of lung cancer include Nucleix Ltd., which uses DNA sequencing for diagnosis.
Customers
growth-positive
Revolutionary blood test will detect stage 1 lung cancer
Israeli startup Savicell is developing a new blood test to diagnose lung cancer. The company uses immunometabolism to measure the metabolic state of immune cells in the blood, allowing for early detection of lung cancer. Savicells diagnostic kit can identify lung cancer with 91 percent sensitivity. The company has conducted research with 200 patients in Israel and has raised $9 million in funding. Savicell is focused on lung cancer but plans to expand its approach to other types of cancer and autoimmune conditions.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.savicell.com |
| Careers | Careers page |
Locations
Matam, Haifa, Israel
Photos & Videos
1 item(s)
Savicell Diagnostics Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
BiologicalsCellsTags (15)
diagnosticsmedical-technologiesblood-testbiotechnologycancerearly-detectionclinical-dataoncologyclinicshospitalsacademialaboratorieshealthcare-providersminimally-invasivepulmonaryGeographic Markets
GlobalSavicell Diagnostics Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Savicell Diagnostics Lifecycle
Savicell Diagnostics News
9 articles
Not applicable
"הצלחנו להציל חיים": כך פועלת הבדיקה שמזהה סרטן בתוך 5 שעות | חדשות 13
A new, simple, and affordable blood test developed in Israel can detect lung cancer within a few hours, potentially saving lives. This test, which has not yet been officially approved, successfully identified the disease in one of the trial participants, saving their life. The test works by asking white blood cells if they have encountered cancer. This breakthrough represents a significant advancement in medical technology and cancer detection, particularly for lung cancer, which is notoriously difficult to diagnose early.
growth-positive
Savicell touts high accuracy results for its liquid biopsy platform
Savicell Diagnostics Ltd. has reported high accuracy results for its liquid biopsy platform Immunobiopsy in identifying lung cancer. The platform achieved 97% sensitivity and 97% specificity in a study with 245 participants. This news is growth-positive for the company.
Customers
growth-positive
Orgenesis to collaborate with Savicell on ImmunoBiopsy platform
Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to develop and validate diagnostic kits for quality control and monitoring purposes in the manufacturing and processing of its cell and gene therapies. Orgenesis will have exclusive rights to use and sell the kits, which will be used within its point-of-care platform. The collaboration aims to enhance the potency of therapies and develop companion diagnostics for targeted patient treatment. The initial focus will be on lung cancer treatments, with plans to expand to other cancer types and diseases. The collaboration will leverage Savicells ImmunoBiopsy platform. The CEO of Orgenesis sees promise in early cancer detection using the technology.
Partners
growth-positive
Startup says its blood test can detect early-stage lung cancer
Israeli startup Savicell Diagnostics has developed a blood test for the early detection of lung cancer. The companys ImmunoBiopsy test analyzes the metabolic profile of the immune system to identify signs of the disease. The test has shown promising results in distinguishing between various ailments, including cancers, autoimmune diseases, and infectious diseases. Savicell has already conducted testing at leading Israeli hospitals and has a more advanced product for lung cancer detection. While the technology is promising, there are still limitations in terms of sensitivity and accuracy. Other companies in the field of liquid biopsy and early detection of lung cancer include Nucleix Ltd., which uses DNA sequencing for diagnosis.
Customers
growth-positive
Revolutionary blood test will detect stage 1 lung cancer
Israeli startup Savicell is developing a new blood test to diagnose lung cancer. The company uses immunometabolism to measure the metabolic state of immune cells in the blood, allowing for early detection of lung cancer. Savicells diagnostic kit can identify lung cancer with 91 percent sensitivity. The company has conducted research with 200 patients in Israel and has raised $9 million in funding. Savicell is focused on lung cancer but plans to expand its approach to other types of cancer and autoimmune conditions.
Customers
growth-positive
A blood test that detects cancer early
Israeli company Savicell is developing a blood test for early diagnosis of cancer based on immuno-metabolism. The test measures the changes in energy utilization within immune system cells when encountering certain diseases. Savicells product has not yet received FDA approval, but a clinical trial in Israel showed promising results with a sensitivity of 91% and specificity of 80%. The company aims to provide earlier diagnosis for lung cancer, which has a higher survival rate when detected at Stage I. Savicell differentiates itself from other companies in the field by focusing on diagnosis rather than therapeutic processes. The companys test is more sensitive and can detect cancer at earlier stages. Savicells competitors mainly focus on sequencing technologies of genetic material secreted by cancer cells.
Customers
growth-positive
Online Disruptive Technologies Announces Publication of Results in Cancer Journal
Online Disruptive Technologies, Inc. announces that its lung cancer clinical study results were published in the scientific journal Cancer Immunology and Immunotherapy. The study validates the promise of Savicells Liquid ImmunoBiopsy platform for the early detection of lung cancer. The platform achieved 91% sensitivity and 80% specificity in diagnosing lung cancer, even in Stage 1. Savicells Well-Shield platform is designed for the early detection of diseases. The companys initial focus is on the cancer liquid biopsy market.
Customers
growth-positive
Online Disruptive Technologies Appoints Executive VP of Research & Development
Online Disruptive Technologies, Inc. has appointed Dr. Shafrira Shai as Executive Vice-President of Research & Development at its subsidiary, Savicell Diagnostic Ltd. Dr. Shai brings 20 years of management experience in medical diagnostics, medical devices, and pharmaceuticals. Savicell has a liquid ImmunoBiopsy platform for early disease detection, with a focus on the cancer liquid biopsy market. The appointment of Dr. Shai is expected to have a positive impact on the companys growth.
Management Changes
N/A
Exact Sciences denies talks underway to invest in Israeli cancer Dx startup
The article does not provide any specific information about Questex LLC.
Savicell Diagnostics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Savicell Diagnostics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514764091 |
| Crunchbase | savicell-diagnostics |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-02T00:00:00.000Z |
| Created | 2014-07-08T00:00:00.000Z |
| Claimed | Yes |